Yet another study reports good success using optical coherence tomography (OCT) as the basis for deciding whether to provide additional Avastin therapy in patients with neovascular age-related macular degeneration (AMD). Thirty-two patients with active subfoveal occult choroidal neovascularisation (CNV) in AMD received a single intravitreal injection of bevacizumab (Avastin) and were reinjected based on new or persisting subretinal or intraretinal fluid on OCT. Patient visits were every 6-8 weeks.After a single injection, 74% of patients demonstrated complete retinal fluid absorption, with 44% of patients showing no relapse during a follow-up of an avewrage of 30 weeks. Fifty-six percent of patients required a second injection after a mean of 19 weeks, with 82% of patients showing absorption of macular fluid thereafter with regain of their previous achieved best-corrected visual acuity .All patients achieved stabilisation of visual acuity during follow-up, with 30% of patients showing a significant gain of >/=3 lines of visual acuity.The researchers conclude that OCT-based reinjections of bevacizumab in neovascular AMD reduce the number of injections and lead to anatomic and functional retinal stabilisation.